Singapore markets closed

PFE Jan 2025 47.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.04000.0000 (0.00%)
As of 11:15AM EDT. Market open.
Full screen
Previous close0.0400
Open0.0700
Bid0.0000
Ask0.0000
Strike47.50
Expiry date2025-01-17
Day's range0.0400 - 0.0700
Contract rangeN/A
Volume4
Open interest9.06k
  • Reuters

    UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year

    Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

  • Reuters

    BioNTech says 90% of 2024 revenues will accrue at end of year

    Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.

  • Business Wire

    Pfizer Announces New Chief Strategy and Innovation Officer

    NEW YORK, May 06, 2024--Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morg